# Presight Capital

> Presight Capital is a VC fund backing Biotechnology and Health Care. See 136 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Los Angeles, United States
- Total investments: 136
- Last investment: Apr 2026
- Lead investor: 11%
- Fund size: $400M
- Last fund: Mar 2021
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/presight-capital/about/
- Website: https://www.presight.vc/

Presight Capital is a venture capital firm investing in the most ambitious founders across sectors, stages, and geographies. Presight takes a global approach to early-stage investment opportunities in software, frontier technologies & biotech, backed by Apeiron, the family office of Christian Angermayer, and a group of world-class investors:Moore Capital, Point72, Mike Novogratz (former CIO of Fortress Investment Group), Martin Chavez (former CFO of Goldman Sachs), Alan Howard (Brevan Howard), Brent Hoberman (Founders Forum), and many successful entrepreneurs and investors who contribute their respective network and experience.

## Contacts

5 contacts available for Presight Capital. Shizune tracks 4 team members at Presight Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/presight-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $2M–$10M |
| Series A | $10M–$75M |
| Series B | $11M–$125M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 21 | 15% |
| Health Care | 18 | 13% |
| Financial Services | 14 | 10% |
| FinTech | 8 | 6% |
| Life Science | 7 | 5% |

91 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 32 | 24% |
| Series A | 25 | 18% |
| Series B | 14 | 10% |
| Series C | 7 | 5% |
| Funding Round | 6 | 4% |

12 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 32 | 24% |
| United Kingdom | 8 | 6% |
| Germany | 4 | 3% |
| India | 3 | 2% |
| Canada | 3 | 2% |

15 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Christian Angermayer | Founder | 46 | https://shizune.co/investors/profile/christian-angermayer |
| Fabian Hansen | Co-founder & General Partner | 76 | https://shizune.co/investors/profile/fabian-hansen |
| Michael Ho | Venture Investor | 0 | https://shizune.co/investors/profile/michael-ho-6a96 |
| Philipp Schreiber | Investment Team | 0 | https://shizune.co/investors/profile/philipp-schreiber |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Alloy Therapeutics | Alloy Therapeutics makes medicine by democratizing access to foundational drug discovery platforms and services. Alloy-Gx, its first platform, is a royalty-free suite of immunocompetent transgenic mice enabling best-in-class in vivo human antibody discovery. Founded in 2017, Alloy Therapeutics is headquartered in Lexington, Massachusetts. | $40M | Series E | Apr 15, 2026 |  |
| Peptilogics | Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space but also ensuring that each potential therapeutic is biologically viable andscalable to manufacture. Peptilogics' lead clinical-stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need. | $78M | Series B | Oct 16, 2025 |  |
| Tern Group | Tern Group is an AI Platform to hire and relocate top healthcare talents globally, faster and cheaper. TERN is a full-stack solution to source and relocate top-tier medical and engineering talent from India, North Africa, South Africa, and Central Asia and the approach ensures a seamless, ethical, and transparent migration process, drasticallycutting complexity and shaving costs for healthcare systems. | $24M | Series A | Sep 10, 2025 |  |
| General Fusion | General Fusion pursues a commercially oriented path toward fusion energy by developing a magnetized target fusion (MTF) technology. The company applies advances in plasma physics, modern electronics, materials, and compression mechanisms to generate fusion-relevant conditions. It operates a demonstration system, Lawson Machine 26 (LM26), thatinjects magnetized plasma into a liquid metal liner and compresses it using coordinated mechanical pistons to reach high temperatures and pressures. The technology serves as a practical stepping stone toward building a fusion demonstration facility and ultimately delivering fusion-derived electricity to the grid. The approach focuses on closing the gap between demonstration milestones and a deployable power-plant system. | $21.6M | Venture - Series Unknown | Aug 21, 2025 |  |
| Divibank | Divibank is a financing platform offering businesses access to growth capital. | $8.2M | Venture - Series Unknown | Apr 02, 2025 |  |
| Needle | Needle operates as an AI-driven platform for search and agent creation. | $2.1M | Seed | Mar 03, 2025 |  |
| Faro | Faro provides inexpensive apparel through re-commerce, collaborating with fashion companies to reduce textile waste and dumping at the manufacturing and consumption levels. | $6M | Seed | Jan 15, 2025 |  |
| Chemomab | Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and blockCCL24 activity. CM-101 has potential to treat multiple severe and life-threatening inflammatory and fibrotic diseases and is currently undergoing clinical development with primary focus for the orphan diseases, Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). Chemomab is advancing in parallel three Phase 2 clinical trials with CM-101 in fibrotic indications and expecting to report data during 2021-2022. | $10M | Post-IPO Equity | Jul 25, 2024 |  |
| TMRW Life Sciences | TMRW is a life sciences technology company setting new standards for transparency, safety, and accountability in IVF and cell management. TMRW's platform, the world's first automated cryo-management for eggs and embryos, provides a complete digital chain of custody fully integrated with a robotic storage and monitoring solution. This isin contrast to the manual and analog methods that have gone unchanged throughout the history of IVF. With TMRW's platform, clinics significantly reduce the chances of potentially devastating errors. The TMRW team includes celebrated innovators in fertility, embryology, cryo-management, automation, software development, and robotics. TMRW is founded by Joshua Abram, Alan Murray, and Dr. Jeffrey Port in 2018 and is based in New York, New York. | $28.2M | Series D | Jul 12, 2024 |  |
| Razor Group | Razor is a global consumer holding company that partners with e-commerce merchants to acquire and scale brands. Razor uses significant growth capital with extensive e-commerce expertise in order to take these acquired merchants to the next stage of development. Razor focuses on specific product categories, long-term value enhancement, andfirst-class customer satisfaction. | $100M | Series D | Mar 04, 2024 |  |

10 of 136 investments shown.

## Co-investors
- [468 Capital](https://shizune.co/investors/profile/468-capital) — VC Fund, 22 deals together
- [MPGI](https://shizune.co/investors/profile/mpgi-2) — VC Fund, 18 deals together
- [Global Founders Capital](https://shizune.co/investors/profile/global-founders-capital) — VC Fund, 15 deals together
- [Valar Ventures](https://shizune.co/investors/profile/valar-ventures) — VC Fund, 15 deals together
- [Founders Fund](https://shizune.co/investors/profile/founders-fund) — VC Fund, 13 deals together
- [redalpine](https://shizune.co/investors/profile/redalpine-venture-partners) — VC Fund, 13 deals together

## Similar investors

### Similar industry
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Global Founders Capital](https://shizune.co/investors/profile/global-founders-capital) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Wamda Capital](https://shizune.co/investors/profile/wamda) — VC Fund
- [F6 Ventures](https://shizune.co/investors/profile/flat6labs) — VC Fund
- [Shorooq Partners](https://shizune.co/investors/profile/shorooq-partners) — VC Fund

## Featured in investor lists
- [Retail Investors](https://shizune.co/investors/retail-investors)
- [Retail VC Funds](https://shizune.co/investors/retail-vc-funds)
- [Retail Investors in Germany](https://shizune.co/investors/retail-investors-germany)
- [Retail VC Funds in Germany](https://shizune.co/investors/retail-vc-funds-germany)
- [Retail VC Funds in Europe](https://shizune.co/investors/retail-vc-funds-europe)
- [Retail Investors in Europe](https://shizune.co/investors/retail-investors-europe)

## FAQ

### What does Presight Capital invest in?

Presight Capital invests primarily in Biotechnology, Health Care and Financial Services startups, most often at Seed and Series A stage. Most of the 136 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Presight Capital's check size?

Presight Capital typically joins rounds of $2M–$10M at Seed, $10M–$75M at Series A and $11M–$125M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Presight Capital participates in.

### How do I contact Presight Capital?

Public channels for Presight Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Presight Capital?

The team at Presight Capital includes Christian Angermayer (Founder), Fabian Hansen (Co-founder & General Partner) and Michael Ho (Venture Investor). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co